2 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 2 Phase 4, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Renal Angiomyolipoma: new trials by email Literature Review of Renal Angiomyolipoma trials Research Report on Renal Angiomyolipoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ivonescimab in the Treatment of Multiple Advanced Tumors Ivocizumab - Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma | Phase 2 | Recruiting | Fudan University | 400 | 2024-11-20 | 2025-08-24 |
| Evaluation of a Simple-Prep Controlled Embolic GPX® Embolic Device - Embolization, Vascular Tumor | Not applicable | Active not recruiting | Fluidx Medical Technology, Inc. | 114 | 2024-11-18 | 2026-03-30 |
| A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) Everolimus - Renal Angiomyolipoma | Phase 4 | Completed | Novartis Pharmaceuticals | 4 | 2023-05-01 | 2026-10-29 |
| Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex. Everolimus - Renal Angiomyolipoma | Phase 4 | Completed | Novartis Pharmaceuticals | 40 | 2018-11-09 | 2021-09-09 |
| Biomarkers for Tuberous Sclerosis Complex (BioTuScCom) Hypomelanotic Macules, Facial Angiofibroma | Terminated | CENTOGENE GmbH Rostock | 20 | 2018-08-01 | 2023-02-10 |
Angiomyolipoma (5) · Tuberous Sclerosis (3) · Lymphangioleiomyomatosis (2) · Astrocytoma (1) · Bone Neoplasms (1) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Kidney Neoplasms (1) · Malformations of Cortical Development (1) · Paget Disease, Extramammary (1) · Paraganglioma (1) · Penile Neoplasms (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Adipose Tissue (5) · Neoplasms, Connective and Soft Tissue (5) · Perivascular Epithelioid Cell Neoplasms (4) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Hamartoma (3) · Heredodegenerative Disorders, Nervous System (3) · Malformations of Cortical Development, Group I (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Multiple Primary (3) · Neoplastic Syndromes, Hereditary (3) · Nervous System Diseases (3)
Everolimus (2)
Novartis Pharmaceuticals (2) · CENTOGENE GmbH Rostock (1) · Fluidx Medical Technology, Inc. (1) · Fudan University (1)
China (2) · Albania (1) · Canada (1) · Egypt (1) · Georgia (1) · India (1) · Lithuania (1) · New Zealand (1) · Pakistan (1) · Romania (1) · Sri Lanka (1) · Taiwan (1) · United States (1)
Hongxia Wang, Doctor (1) · Michael Darcy, MD (1) · Peter Bauer, Prof.Dr (1)